What is the additive efficacy of quadruple drug therapy for patients who have #HFmrEF and #HFpEF? Get the answer here: bit.ly/3vMESpP #JACCHF

🔑 Colchicine 0.5 mg daily is FDA-approved for secondary prevention in patients w/ coronary artery disease. Read key points to remember from a state-of-the-art review on the long-term safety of low-dose colchicine for atherosclerosis: bit.ly/4aUjBJN #cvPrev

Quick trip up to Boston on my CCU rotation day off to attend #HRS2024 and present an interesting case of dynamic ECG patterns of LVH/LV strain in a HCM patient who started, discontinued and then restarted mavacamten. Nosheen Reza, MD, MS Anjali Owens

Application period for the next cohorts of the American College of Cardiology Internal Medicine Cardiology Programs is now open! Please share with your mentees — deadline is 10/15 Learn more & apply: acc.org/About-ACC/Dive… Melanie S. Sulistio, MD Melvin R. Echols, MD, MSCR, FACC, FHFSA, FASPC Quinn Capers, IV Jennifer H. Mieres, MD , FACC, MASNC, FAHA Mayra Guerrero, MD

Can cardiac myosin inhibition alter adverse ECG changes associated with HCM? Check out our newly published case report! 🫀 Nosheen Reza, MD, MS Anjali Owens @deFeriaMD jacc.org/doi/10.1016/j.…

In this new #JACCCaseReports Clinical Vignette Corner, Dr. Melissa Austin, MD, et al discuss a case of a 60 y/o man w/ #cvHCM treated with the novel cardiac myosin inhibitor, mavacamten bit.ly/4gXqtKj Nosheen Reza, MD, MS Anjali Owens

A new Elsevier | ScienceDirect 📄 by Nosheen Reza, MD, MS et al. discusses the use of gamification, a technique based on #behavioralscience principles, to incentivize diverse & improved enrollment in trials. Read it here 👉 spr.ly/6019U4KKZ #CardiologyTrial

Difficult to demonstrate true disease modification in any lower risk disease state, esp among younger-to-middle age adults Intriguing N-of-1-trial-like observation here of normalization of LVH electrocardiographic signature w CMI mavacamten w recurrence upon its discontinuation.

Excited for a fun weekend of 🫀! #AHA24 AHA Science

A new case study highlights: ➡️a 60 y/o man with hypertrophic #cardiomyopathy treated w/ novel cardiac myosin inhibitor ➡️how myosin inhibition positively alters adverse electrical changes due to #HCM spr.ly/6011sy3mc 🩺 Nosheen Reza, MD, MS @deFeriaMD Melissa Austin, MD Anjali Owens

Fantastic work from our Penn Women in Cardiology of the Penn Cardiology Center for Inherited Cardiovascular Disease, Anjali Owens & Nosheen Reza, MD, MS, and University of Penn IM Residency Program and future cardiologist, Melissa Austin, MD! 🧬🫀

Excited to be heading to NYU for Cardiology fellowship in July! 🫀🩺NYU Langone Health NYC Health + Hospitals/Bellevue

Congratulations to the incoming NYU Langone Health cardiology fellows! Looking forward to working with you.

Can't wait to work and learn alongside this fabulous group of future cardiologists! 🫀 #WIC NYU Langone Health

Women are underrepresented as speakers at grand rounds across the U.S. Over a 25-year period, the proportion of female speakers increased by approximately 1% per year, a small but "good sign" of forward progress, said the study's senior author Nosheen Reza, MD, MS. spr.ly/6016a8SVa

Check out our new publication in JACC Journals #JACCEP describing our experience screening for arrhythmias and managing AF/AFL in a contemporary cohort of myotonic muscular dystrophy patients Saman Nazarian, MD, PhD Penn Cardiology jacc.org/doi/10.1016/j.…

Congratulations Melissa Austin, MD

Grateful for the opportunity to present our moderated poster on mavacamten use in patients with oHCM and prior SRT! #ACC25 #HCM Many thanks to our phenomenal mentors Nosheen Reza, MD, MS Anjali Owens and ✨ co-authors Esther Duqueney Melissa Austin, MD, Parth Patel! jacc.org/doi/epdf/10.10…

1/ Cardiac MRI is an important tool in the evaluation of dilated & arrhythmogenic cardiomyopathies. A novel pattern of late gadolinium enhancement was the clue to the diagnosis in this case of early-onset atrial fibrillation, now online in CircImaging Melissa Austin, MD Nosheen Reza, MD, MS

There is a high prevalence of AF/AFL in this single-institution MMD cohort, and incidence of AF/AFL increased over time. The CHA2DS2-VASc score may not be an effective tool in this population. Additional studies needed jacc.org/doi/10.1016/j.… #JACCCEP #AFib Melissa Austin, MD